164 related articles for article (PubMed ID: 19503098)
1. Reactive oxygen species and lipoxygenases regulate the oncogenicity of NPM-ALK-positive anaplastic large cell lymphomas.
Thornber K; Colomba A; Ceccato L; Delsol G; Payrastre B; Gaits-Iacovoni F
Oncogene; 2009 Jul; 28(29):2690-6. PubMed ID: 19503098
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of NPM-ALK by siRNA causes anaplastic large cell lymphoma cell growth inhibition and augments the anti cancer effects of chemotherapy in vitro.
Hsu FY; Zhao Y; Anderson WF; Johnston PB
Cancer Invest; 2007 Jun; 25(4):240-8. PubMed ID: 17612934
[TBL] [Abstract][Full Text] [Related]
3. Role of signal transducer and activator of transcription 5 in nucleophosmin/ anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells.
Nieborowska-Skorska M; Slupianek A; Xue L; Zhang Q; Raghunath PN; Hoser G; Wasik MA; Morris SW; Skorski T
Cancer Res; 2001 Sep; 61(17):6517-23. PubMed ID: 11522649
[TBL] [Abstract][Full Text] [Related]
4. B7-H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma.
Yamamoto R; Nishikori M; Tashima M; Sakai T; Ichinohe T; Takaori-Kondo A; Ohmori K; Uchiyama T
Cancer Sci; 2009 Nov; 100(11):2093-100. PubMed ID: 19703193
[TBL] [Abstract][Full Text] [Related]
5. The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner.
Hsu FY; Johnston PB; Burke KA; Zhao Y
Cancer Res; 2006 Sep; 66(18):9002-8. PubMed ID: 16982741
[TBL] [Abstract][Full Text] [Related]
6. Activation of Rac1 and the exchange factor Vav3 are involved in NPM-ALK signaling in anaplastic large cell lymphomas.
Colomba A; Courilleau D; Ramel D; Billadeau DD; Espinos E; Delsol G; Payrastre B; Gaits-Iacovoni F
Oncogene; 2008 Apr; 27(19):2728-36. PubMed ID: 17998938
[TBL] [Abstract][Full Text] [Related]
7. Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma.
Amin HM; McDonnell TJ; Ma Y; Lin Q; Fujio Y; Kunisada K; Leventaki V; Das P; Rassidakis GZ; Cutler C; Medeiros LJ; Lai R
Oncogene; 2004 Jul; 23(32):5426-34. PubMed ID: 15184887
[TBL] [Abstract][Full Text] [Related]
8. Apoptosis of W256 carcinosarcoma cells of the monocytoid origin induced by NDGA involves lipid peroxidation and depletion of GSH: role of 12-lipoxygenase in regulating tumor cell survival.
Tang DG; Honn KV
J Cell Physiol; 1997 Aug; 172(2):155-70. PubMed ID: 9258337
[TBL] [Abstract][Full Text] [Related]
9. Serine phosphorylation of NPM-ALK, which is dependent on the auto-activation of the kinase activation loop, contributes to its oncogenic potential.
Wang P; Wu F; Zhang J; McMullen T; Young LC; Ingham RJ; Li L; Lai R
Carcinogenesis; 2011 Feb; 32(2):146-53. PubMed ID: 21045017
[TBL] [Abstract][Full Text] [Related]
10. ALK mutants in the kinase domain exhibit altered kinase activity and differential sensitivity to small molecule ALK inhibitors.
Lu L; Ghose AK; Quail MR; Albom MS; Durkin JT; Holskin BP; Angeles TS; Meyer SL; Ruggeri BA; Cheng M
Biochemistry; 2009 Apr; 48(16):3600-9. PubMed ID: 19249873
[TBL] [Abstract][Full Text] [Related]
11. Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase.
Turner SD; Tooze R; Maclennan K; Alexander DR
Oncogene; 2003 Oct; 22(49):7750-61. PubMed ID: 14586401
[TBL] [Abstract][Full Text] [Related]
12. Anaplastic lymphoma kinase (ALK)-induced malignancies: novel mechanisms of cell transformation and potential therapeutic approaches.
Wasik MA; Zhang Q; Marzec M; Kasprzycka M; Wang HY; Liu X
Semin Oncol; 2009 Apr; 36(2 Suppl 1):S27-35. PubMed ID: 19393833
[TBL] [Abstract][Full Text] [Related]
13. Identification of NPM-ALK interacting proteins by tandem mass spectrometry.
Crockett DK; Lin Z; Elenitoba-Johnson KS; Lim MS
Oncogene; 2004 Apr; 23(15):2617-29. PubMed ID: 14968112
[TBL] [Abstract][Full Text] [Related]
14. Global proteome profiling of NPM/ALK-positive anaplastic large cell lymphoma.
Sjostrom C; Seiler C; Crockett DK; Tripp SR; Elenitoba Johnson KS; Lim MS
Exp Hematol; 2007 Aug; 35(8):1240-8. PubMed ID: 17560012
[TBL] [Abstract][Full Text] [Related]
15. Identification of multiple SNT-binding sites on NPM-ALK oncoprotein and their involvement in cell transformation.
Chikamori M; Fujimoto J; Tokai-Nishizumi N; Yamamoto T
Oncogene; 2007 May; 26(20):2950-4. PubMed ID: 17086210
[TBL] [Abstract][Full Text] [Related]
16. Identification of a novel crosstalk between casein kinase 2α and NPM-ALK in ALK-positive anaplastic large cell lymphoma.
Armanious H; Gelebart P; Anand M; Lai R
Cell Signal; 2013 Feb; 25(2):381-8. PubMed ID: 23153582
[TBL] [Abstract][Full Text] [Related]
17. Alpha-tocopherol attenuates the anti-tumor activity of crizotinib against cells transformed by NPM-ALK.
Uchihara Y; Ueda F; Tago K; Nakazawa Y; Ohe T; Mashino T; Yokota S; Kasahara T; Tamura H; Funakoshi-Tago M
PLoS One; 2017; 12(8):e0183003. PubMed ID: 28806414
[TBL] [Abstract][Full Text] [Related]
18. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death.
Zamo A; Chiarle R; Piva R; Howes J; Fan Y; Chilosi M; Levy DE; Inghirami G
Oncogene; 2002 Feb; 21(7):1038-47. PubMed ID: 11850821
[TBL] [Abstract][Full Text] [Related]
19. Mice transgenic for NPM-ALK develop non-Hodgkin lymphomas.
Jäger R; Hahne J; Jacob A; Egert A; Schenkel J; Wernert N; Schorle H; Wellmann A
Anticancer Res; 2005; 25(5):3191-6. PubMed ID: 16101126
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of pyridoisoquinoline derivatives F91873 and F91874, novel multikinase inhibitors with activity against the anaplastic lymphoma kinase.
Kruczynski A; Mayer P; Marchand A; Vispé S; Fournier E; Annereau JP; Brel V; Barret JM; Delsol G; Imbert T; Fahy J; Bailly C
Anticancer Drugs; 2009 Jun; 20(5):364-72. PubMed ID: 19322071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]